Effects of troglitazone on atherogenic lipoprotein phenotype in coronary patients with insulin resistance

被引：33

作者：

Sunayama, S ^{[1
]}

Watanabe, Y ^{[1
]}

Ohmura, H ^{[1
]}

Sawano, M ^{[1
]}

Shimada, K ^{[1
]}

Mokuno, H ^{[1
]}

Daida, H ^{[1
]}

Yamaguchi, H ^{[1
]}

机构：

[1] Juntendo Univ, Dept Cardiol, Bunkyo Ku, Tokyo 1138421, Japan

来源：

ATHEROSCLEROSIS | 1999年 / 146卷 / 01期

关键词：

insulin resistance syndrome; lipoprotein lipase; LDL size; triglycerides; coronary artery disease;

D O I：

10.1016/S0021-9150(99)00138-0

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Insulin resistance is associated with atherogenic lipoprotein phenotype, including small dense LDL particle, hypertriglycemia and low HDL cholesterol levels. Troglitazone, a novel insulin sensitizing agent, may improve the associated lipid profile in patients with insulin resistance. We examined the effects of troglitazone (400 mg daily for 12 weeks) in 12 non-diabetic coronary patients (60 +/- 10 years), all of whom had hyperinsulinemic response to an oral glucose load. Troglitazone markedly reduced the insulin response. After the treatment, plasma triglycerides decreased by 32% (P < 0.05), HDL cholesterol increased by 11% (P < 0.05) and LDL peak particle diameter increased from 24.7 +/- 0.3 to 25.5 +/- 0.5 nm (P < 0.01). These lipidic improvements were associated with a significant rise in postheparin lipoprotein lipase levels (175 +/- 52 to 217 +/- 69 ng/ml, P < 0.01). In patients with insulin resistance syndrome, troglitazone improved the atherogenic lipoprotein phenotype as well as hyperinsulinemia. Our data suggest that troglitazone therapy could reduce the atherosclerotic risk due to insulin resistance even in non-diabetic patients. (C) 1999 Elsevier Science Ireland Ltd. All rights reserved.

引用

页码：187 / 193

页数：7

共 33 条

[1] Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone [J].

Antonucci, T ;

Whitcomb, R ;

McLain, R ;

Lockwood, D .

DIABETES CARE, 1997, 20 (02) :188-193

[2]

AUSTIN MA, 1988, JAMA-J AM MED ASSOC, V260, P1917

[3] ATHEROGENIC LIPOPROTEIN PHENOTYPE - A PROPOSED GENETIC-MARKER FOR CORONARY HEART-DISEASE RISK [J].

AUSTIN, MA ;

KING, MC ;

VRANIZAN, KM ;

KRAUSS, RM .

CIRCULATION, 1990, 82 (02) :495-506

[4] ACTIVITIES OF LIPOPROTEIN-LIPASE AND HEPATIC TRIGLYCERIDE LIPASE IN POSTHEPARIN PLASMA OF PATIENTS WITH LOW CONCENTRATIONS OF HDL CHOLESTEROL [J].

BLADES, B ;

VEGA, GL ;

GRUNDY, SM .

ARTERIOSCLEROSIS AND THROMBOSIS, 1993, 13 (08) :1227-1235

[5]

ECKEL RH, 1989, NEW ENGL J MED, V320, P1060

[6]

FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499

[7] Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women [J].

Gardner, CD ;

Fortmann, SP ;

Krauss, RM .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (11) :875-881

[8] Insulin resistance in the pathogenesis of dyslipidemia [J].

Garg, A .

DIABETES CARE, 1996, 19 (04) :387-389

[9]

Gavin JR, 1997, DIABETES CARE, V20, P1183

[10] Cardiac and glycemic benefits of troglitazone treatment in NIDDM [J].

Ghazzi, MN ;

Perez, JE ;

Autonucci, TK ;

Driscoll, JH ;

Huang, SM ;

Faja, BW ;

Whitcomb, RW .

DIABETES, 1997, 46 (03) :433-439

← 1 2 3 4 →